• News

"Dr. Llovet On Biomarkers For HCC" -Josep M. Llovet, MD, PhD

  • OncLive
  • New York, NY
  • (September 14, 2018)

Josep Llovet, MD, PhD, director and founder of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine at Mount Sinai, discusses the potential for biomarkers to improve the treatment of patients with hepatocellular carcinoma (HCC). Immune checkpoints, such as PD-L1, are expressed in a variety of immune cells, and PD-1/PD-L1 inhibitors designed to block these molecules are proven to be effective against a wide spectrum of malignancies. While checkpoint inhibitors provide a great deal of hope for patients, in the future, it will be key to understand why some patients respond well to these therapies while others do not.

- Josep M. Llovet, MD, PhD, Director, Founder, The Liver Cancer Program, Professor, Medicine, Icahn School of Medicine at Mount Sinai

Learn more